NEWS
SHL Medical | 2019.06

Auto-Injector Designed by SHL Medical Selected as Finalist in 2019 Medical Design Excellence Awards

Image credit: Medical Device and Diagnostic Industry

SHL Group is pleased to announce that AstraZeneca's BYDUREON BCise auto-injector, which is designed and manufactured by SHL Medical, has been selected as a finalist in the Drug-Delivery and Combination Products category of the 21st Annual Medical Design Excellence Awards (MDEA) competition.1

SHL is proud to have been involved in the design, development, and manufacturing of cartridge-based BYDUREON BCise auto-injector in partnership with AstraZeneca. The injector is equipped with SHL's proprietary Needle Isolation Technology (NIT®), a unique safety solution that enables cartridges to function like traditional prefilled, staked-needle syringes. Featuring a pre-installed needle that is permanently hidden throughout the injection process, this technology eliminates the need for patients to manually attach the needle before each injection. Production of the device is driven by SHL's full set of in-house capabilities and fully automated assembly processes to meet the demands for high-volume production.

"SHL has always supported our pharmaceutical partners with innovative solutions that enable them to empower their patients. The MDEA nomination is an affirmation of SHL's dedication to doing just that—empowering AstraZeneca's patients with a simplified device for a more convenient injection experience," said SHL Medical Chief Commercial Officer Josh Gonzalez.

Jochen Ratjen, director of industrial design said, "Building an easy-to-use auto-injector around a cartridge was a new challenge that involved an unprecedented level of attention to multiple factors surrounding the drug, the needle attachment, and the overall injection process. Therefore, the users were essential in determining the device's activation mechanism and form factor. SHL worked closely with AstraZeneca throughout the entire development phase to ensure that the design made sense to drug's nature as well as the end-user."

The MDEA is the medtech industry's premier design competition committed to recognizing significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. The awards program celebrates the accomplishments of the medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the cutting-edge products that are saving lives; improving patient healthcare; and transforming medtech—one innovation at a time.

Finalists were officially announced in the May Issue of MD+DI (Medical Device and Diagnostic Industry) magazine. Winners will be announced at the 2019 MDEA Ceremony held Tuesday, June 11, 2019 in conjunction with UBM's Medical Design & Manufacturing (MD&M) East event at the Jacob K. Javits Convention Center in New York.

關於瑞健

瑞健集團為領航全球先進藥物輸送系統產業的設計、研發、及製造龍頭。其事業據點涵蓋位於瑞士、瑞典、美國及台灣的現代化設計中心以及設立於亞洲的先進製造廠房。 瑞健主要客戶為世界知名藥廠以及生技公司,提供如自動化注射器,筆型注射器以及吸入器等高科技產品。瑞健持續投資於研發製造為開發新型高科技藥物輸送系統以符合市場趨勢,其中包括使用步驟簡化、注射器精密化、拋棄式/複用式多重選擇、劑量彈性化以及藥劑濃稠度之配合等。

瑞健目前全球已有超過 4,000 名員工,主要分為以下事業群:

SHL Medical 主要為製藥和生技企業設計、研發、及製造高科技藥物傳輸系統,也提供終端組裝、醫材標籤及包裝相關服務

SHL Healthcare 從事居家及醫院護理器材之研發製造

SHL Technologies 提供醫療科技及工業設備之 OEM 製造與相關服務

如欲更深入了解瑞健集團,請至公司網站 www.shl.group.

瑞健媒體聯絡人

info@shl-group.com